Glaucoma, the world's first irreversible blindness, is a collective name for a group of diseases that cause progressive optic nerve damage and eventually impair vision. It is a common ophthalmic disease in which pathologically elevated intraocular pressure leads to optic nerve atrophy and depression, visual field defects and vision loss.
Glaucoma has a continuum of visual field changes from very mild and very early to very severe and very advanced. Glaucoma patients look at the world and their vision changes.
The pathogenesis of glaucoma is generally caused by poor atrial fluid circulation resulting in elevated intraocular pressure, which in normal people is 10 to 20 mm Hg and can be measured using a manometer.
The principle of treatment for glaucoma is to lower the intraocular pressure, and drug treatment mainly includes eye drops and oral IOP-lowering drugs.
We have been working on a comprehensive and broad basic research and transformative drug development in glaucoma to make it easier for people with glaucoma to achieve healthy vision. Learn about glaucoma and explore how it all began, where research is progressing now, and our vision for the future.
Online Inquiry
Send us an email with any questions or inquiries.
Ace Therapeutics is an innovative eye disease research company that offers a wide range of services in basic research, drug development and preclinical research for glaucoma, providing innovative and high-quality solutions to its customers.
Important Links
Company
